Other limitations include unknown group differences in risk factors of cognitive decline and AD, such as apolipoprotein E ε4 genotype, and inflammation, although there were no significant differences between groups in terms of hypertension, diabetes mellitus, medications, biomarkers of lipid metabolism, physical performance, instrumental ADL functioning, or depressive mood. This evidence concerns the gene APOE and diabetes mellitus.